Digital therapeutics company HealthBeacon said it has added a further five clients so far this year, in addition to its 18 clients at the time of IPO in December.
The company listed on the Euronext Growth Dublin in December, raising €25m in funding.
The Dublin headquartered firm develops products for managing injectable medications for people in the home.
The new clients include three pharmaceutical companies and two programmes through the UK's National Health Service (NHS) and the Irish Health Service Executive (HSE).
It said its new clients will further strengthen its customer base which now includes Amryt, Novartis, NHS, HSE, Sanofi, Accord Healthcare, Clonmel Healthcare, Teva, Viatris, and AbbVie.
HealthBeacon said the new deals and continued rollout of its technology and services through pharmaceutical companies and governments underpins its target of 100,000 units by the end of 2023 and the potential for further significant growth in the medium term.
The company also said it remains focused on expanding its client base within pharmaceutical companies, specialty pharmacy, healthcare organisations and governments and deepening its existing relationships.
Jim Joyce, CEO and co-founder of HealthBeacon, said its new client wins add to the very significant momentum in the business as leading pharma companies and health systems adopt its technology.
Mr Joyce said that one in two patients on chronic and critical self-administered injectable medications fail to initiate treatment or discontinue therapy within the first 12 months.
"HealthBeacon's technology and services supports those patients and enhances their likelihood of success on these important medications, something that is increasingly recognised by many of the world's largest healthcare organisations," he added.
